This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
FDA Grants Priority Review to Roche's Early-Stage Breast Cancer NDA
by Zacks Equity Research
RHHBY's giredestrant as an adjuvant treatment for early-stage breast cancer won FDA Priority Review, backed by encouraging phase III data versus standard therapy.
RHHBYNegative Net Change LQDAPositive Net Change IMCRNegative Net Change INDVPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
MRNA Partners With CEPI to Develop Vaccine for Bundibugyo Ebolavirus
by Zacks Equity Research
Moderna gains up to $50M from CEPI to advance a Bundibugyo ebolavirus vaccine as the partnership expands amid an ongoing Ebola outbreak.
MRNAPositive Net Change IMCRNegative Net Change INDVPositive Net Change
biotechs medical pharmaceuticals vaccines
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate
by Zacks Equity Research
Agios gains global rights to cevidoplenib for ITP, adding a late-stage rare hematology asset with up to $1B U.S. peak sales potential.
AGIOPositive Net Change LQDAPositive Net Change IMCRNegative Net Change INDVPositive Net Change
biotechs
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug
by Zacks Equity Research
Replimune stock surges after the company aligned with the FDA on plans to resubmit its BLA for RP1 plus Opdivo in advanced melanoma.
BMYPositive Net Change REPLPositive Net Change LQDAPositive Net Change IMCRNegative Net Change
biotechs
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)
by Zacks Equity Research
REGN tops Q1 estimates with strong Dupixent and Eylea HD growth, but the stock slips as Eylea sales plunge and competition intensifies.
REGNPositive Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO
by Zacks Equity Research
BMY unveils strong ASCO data for mezigdomide and pumitamig, highlighting late-stage pipeline progress across myeloma and lung cancer.
BMYPositive Net Change LQDAPositive Net Change BNTXNegative Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes
by Zacks Equity Research
Agios discontinues development of tebapivat in lower-risk MDS after a phase IIb study misses efficacy goals, shifting focus to a phase II SCD program.
AGIOPositive Net Change LQDAPositive Net Change IMCRNegative Net Change INDVPositive Net Change
biotechs
Vertex Stock Down Nearly 8% in 3 Months: Time to Buy or Stay Cautious?
by Kinjel Shah
VRTX stock falls 7.9% in three months as Journavx and Casgevy sales missed expectations, but CF growth, Alyftrek momentum and renal pipeline progress stand out.
VRTXPositive Net Change MRNAPositive Net Change CRSPPositive Net Change
biotechs
RVMD Stock Rises on Detailed Results From Pancreatic Cancer Study
by Zacks Equity Research
Revolution Medicines jumps after detailed phase III data show daraxonrasib cuts death risk by 60% and doubles median survival in treated pancreatic cancer.
BMYPositive Net Change SMMTPositive Net Change RVMDPositive Net Change TNGXNegative Net Change
biotechs medical
IBRX and the BCG Shortage: Deals That Could Expand Demand
by Sundeep Ganoria
ImmunityBio targets the BCG shortage with new supply deals and label expansion efforts that could strengthen Anktiva demand in bladder cancer.
MRKNegative Net Change URGNPositive Net Change IBRXNegative Net Change
biotechs medical